Revenue

12 Months Ended

Dec. 31, 2022

Revenue from Contract with Customer [Abstract]

Revenue

REVENUE

The Company develops, manufactures and sells devices designed primarily for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and blocking pain by temporarily ablating peripheral nerves. These devices are marketed to a broad base of medical centers globally.

In 2022, the Company changed the presentation of its disaggregated revenue within the notes to the Consolidated Financial Statements to align with current product line offerings. Specifically, pain management revenue, representing

sales of the cryoSPHERE® product, was historically presented within open ablation revenue and is now a separately stated revenue product type. Valve revenue, historically presented as a separate product type revenue, is now included in open ablation revenue. Revenue amounts for comparative prior fiscal periods have been reclassified to conform to the current period presentation.

United States revenue by product type is as follows:

	2022		2021		2020
Open ablation	$	86,119	$	72,396	$	65,301
Minimally invasive ablation	38,553		39,380		25,647
Pain management	39,974		22,787		11,315
Total ablation	$	164,646	$	134,563	$	102,263
Appendage management	112,555		94,568		66,981
Total United States	$	277,201	$	229,131	$	169,244

International revenue by product type is as follows:

	2022		2021		2020
Open ablation	$	26,809	$	23,194	$	18,760
Minimally invasive ablation	5,986		6,409		6,171
Pain management	558		61		3
Total ablation	$	33,353	$	29,664	$	24,934
Appendage management	19,825		15,534		12,353
Total International	$	53,178	$	45,198	$	37,287

Revenue attributed to customer geographic locations is as follows:

	2022		2021		2020
United States	$	277,201	$	229,131	$	169,244
Europe	30,428		27,931		23,217
Asia	20,734		16,077		13,118
Other International	2,016		1,190		952
Total International	53,178		45,198		37,287
Total Revenue	$	330,379	$	274,329	$	206,531